Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"

被引：14

作者：

Ascierto, Paolo A. ^{[1
]}

Grimaldi, Antonio M. ^{[1
]}

Acquavella, Nicolas ^{[2
]}

Borgognoni, Lorenzo ^{[3
]}

Calabro, Luana ^{[4
]}

Cascinelli, Natale ^{[5
]}

Cesano, Alessandra ^{[6
]}

Del Vecchio, Michele ^{[7
]}

Eggermont, Alexander M. ^{[8
]}

Faries, Mark ^{[9
]}

Ferrone, Soldano ^{[10
]}

Fox, Bernard A. ^{[11
,12
]}

Gajewski, Thomas F. ^{[13
]}

Galon, Jerome ^{[14
,15
,16
]}

Gnjatic, Sacha ^{[17
]}

Gogas, Helen ^{[18
]}

Kashani-Sabet, Mohammed ^{[19
]}

Kaufman, Howard L. ^{[20
]}

Larkin, James ^{[21
]}

Lo, Roger S. ^{[22
,23
]}

Mantovani, Alberto ^{[24
]}

Margolin, Kim ^{[25
]}

Melief, Cornelis ^{[26
,27
]}

McArthur, Grant ^{[28
]}

Palmieri, Giuseppe ^{[29
]}

Puzanov, Igor ^{[30
]}

Ribas, Antoni ^{[31
]}

Seliger, Barbara ^{[32
]}

Sosman, Jeff ^{[33
]}

Suenaert, Peter ^{[34
]}

Tarhini, Ahmad A. ^{[35
]}

Trinchieri, Giorgio ^{[36
]}

Vidal-Vanaclocha, Fernando ^{[37
,38
]}

Wang, Ena ^{[39
,40
]}

Ciliberto, Gennaro ^{[1
]}

Mozzillo, Nicola ^{[1
]}

Marincola, Francesco M. ^{[41
]}

Thurin, Magdalena ^{[42
]}

机构：

[1] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy

[2] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[3] SM Annunziata Hosp, Reg Melanoma Refferral Ctr, Florence, Italy

[4] Univ Hosp Siena, Ist Toscano Tumori, Siena, Italy

[5] WHO, Melanoma Program, Milan, Italy

[6] Nodality Inc, San Francisco, CA USA

[7] Ist Nazl Tumori, Fdn IRCCS, Dept Med Oncol, I-20133 Milan, Italy

[8] Canc Inst Gustave Roussy, Paris, France

[9] John Wayne Canc Inst, Santa Monica, CA USA

[10] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA

[11] Providence Portland Med Ctr, Robert W Franz Canc Ctr, Earle A Chiles Res Inst, Lab Mol & Tumor Immunol, Portland, OR USA

[12] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA

[13] Univ Chicago, Chicago, IL 60637 USA

[14] INSERM, Lab Integrat Canc Immunol, U872, F-75006 Paris, France

[15] Univ Paris 05, Paris, France

[16] Univ Paris 06, Ctr Rech Cordeliers, Paris, France

[17] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[18] Univ Athens, Sch Med, Dept Med 1, GR-11527 Athens, Greece

[19] Calif Pacific Med Ctr, Res Inst, Ctr Melanoma Res & Treatment, San Francisco, CA USA

[20] Rush Univ, Chicago, IL 60612 USA

[21] Royal Marsden NHS Fdn Trust, London, England

[22] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[23] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA

[24] Humanitas Clin & Res Inst, Rozzano, Italy

[25] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[26] Leiden Univ, Med Ctr, Leiden, Netherlands

[27] ISA Pharmaceut, Leiden, Netherlands

[28] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia

[29] CNR, Inst Biomol Chem, Unit Canc Genet, Sassari, Italy

[30] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[31] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Tumor Immunol Programme, Los Angeles, CA 90095 USA

[32] Univ Halle Wittenberg, Inst Med Immunol, D-06108 Halle, Germany

[33] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA

[34] GlaxoSmithKline Vaccines, Global Early Clin Dev, Clin Immunotherapeut, Immunotherapeut, Rixensart, Belgium

[35] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[36] NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA

[37] CEU San Pablo Univ, Inst Appl Mol Med IMMA, Madrid 28668, Spain

[38] HM Hosp, Sch Med, Madrid 28668, Spain

[39] NIH, Infect Dis & Immunogenet Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA

[40] NIH, Ctr Human Immunol, Bethesda, MD 20892 USA

[41] Sidra Med & Res Ctr, Doha, Qatar

[42] NCI, Canc Diag Program, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷

关键词：

ADJUVANT INTERFERON THERAPY; HIGH-RISK MELANOMA; SENTINEL LYMPH-NODES; METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; PEGYLATED INTERFERON-ALPHA-2B; BRAF(V600E) INHIBITION; SIGNALING PATHWAY; PREDICTIVE MARKER; PERIPHERAL-BLOOD;

D O I：

10.1186/1479-5876-11-137

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third "Melanoma Research: " A bridge from Naples to the World" meeting, shortened as " Bridge Melanoma Meeting" took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

引用

页数：28

共 115 条

[1]

Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? [J].